WEI-WU HE, Ph.D. 13D and 13G filings for CASI Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-01-29 7:21 pm Purchase | 2026-01-27 | 13D | CASI Pharmaceuticals, Inc. CASI | WEI-WU HE, Ph.D. | 8,965,535 34.800% | 5,000,000 (+126.09%) | Filing |
| 2026-01-09 06:03 am Unchanged | 2026-01-09 | 13D | CASI Pharmaceuticals, Inc. CASI | WEI-WU HE, Ph.D. | 3,965,535 19.100% | 0 (Unchanged) | Filing |
| 2025-12-18 06:01 am Purchase | 2025-12-18 | 13D | CASI Pharmaceuticals, Inc. CASI | WEI-WU HE, Ph.D. | 3,965,535 19.100% | 230,000 (+6.16%) | Filing |
| 2025-06-20 4:30 pm Purchase | 2025-06-16 | 13D | CASI Pharmaceuticals, Inc. CASI | WEI-WU HE, Ph.D. | 3,735,535 23.800% | 477,644 (+14.66%) | Filing |
| 2024-08-12 08:27 am Purchase | 2024-07-15 | 13D | CASI Pharmaceuticals, Inc. CASI | WEI-WU HE, Ph.D. | 3,257,891 20.940% | 420,000 (+14.80%) | Filing |
| 2023-04-18 4:00 pm Purchase | 2023-04-14 | 13D | CASI Pharmaceuticals, Inc. CASI | WEI-WU HE, Ph.D. | 2,837,891 19.750% | 2,837,891 (New Position) | Filing |